Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · September 12, 2024

Olaparib Plus Trastuzumab for HER2-Positive Advanced Breast Cancer With Germline BRCA1/2 Mutations

The Breast

 

Additional Info

The Breast
Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study
Breast 2024 Aug 02;77(xx)103780, JE Alés-Martínez, J Balmaña, P Sánchez-Rovira, FJ Salvador Bofill, JÁ García Sáenz, I Pimentel, S Morales, M Fernández-Abad, A Lahuerta Martínez, N Ferrer, P Zamora, B Bermejo, T Díaz-Redondo, MH López-Ceballos, M Galán, J Pérez-Escuredo, L Calabuig, M Sampayo, JM Pérez-Garcia, J Cortés, A Llombart-Cussac

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading